Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Sold by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC lowered its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 4.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 216,298 shares of the medical instruments supplier’s stock after selling 9,568 shares during the period. Greenwood Capital Associates LLC owned about 0.50% of Harvard Bioscience worth $456,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Harvey Partners LLC grew its position in Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after buying an additional 157,500 shares during the last quarter. Williams & Novak LLC bought a new stake in shares of Harvard Bioscience during the 4th quarter worth $209,000. Barclays PLC grew its holdings in shares of Harvard Bioscience by 304.4% in the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 44,150 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Harvard Bioscience by 19.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 180,006 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 29,607 shares during the period. Finally, Brighton Jones LLC purchased a new stake in shares of Harvard Bioscience during the third quarter valued at $68,000. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Trading Up 1.2 %

Shares of HBIO opened at $1.67 on Wednesday. The business’s 50-day moving average price is $2.06 and its 200 day moving average price is $2.46. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $72.85 million, a P/E ratio of -5.06 and a beta of 1.25. Harvard Bioscience, Inc. has a 1-year low of $1.63 and a 1-year high of $4.93.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.